The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis
The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis
About this item
Full title
Author / Creator
Publisher
United States: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
The soluble urokinase receptor (suPAR) promotes proteinuria and induces focal segmental glomerulosclerosis (FSGS)-like lesions in mice. A serum suPAR concentration cutoff of 3000pg/ml has been proposed as a clinical biomarker for patients with FSGS. Interestingly, several studies in patients with glomerulopathy found an inverse correlation between...
Alternative Titles
Full title
The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1504152284
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1504152284
Other Identifiers
ISSN
0085-2538
E-ISSN
1523-1755
DOI
10.1038/ki.2013.505
